Accessibility Menu
Vita Life Sciences logo

Vita Life Sciences(ASX) VLS

Market CapA$132.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+2,458%
5 Year+177%
1 Year+19%
1 Month+1%
A$2.45
-1.61%
-0.04Today
Vita Life Sciences last closing stock price
MetricPriceDate
Last closeAUD 2.492026-08-13
Vita Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.4%AUD 2.482026-08-06
1 month+1.22%AUD 2.462026-07-14
3 month+2.89%AUD 2.422026-05-14
Year to date+0.22%AUD 2.482025-12-31
1 year+18.55%AUD 2.102025-08-13
3 year+92.57%AUD 1.292023-08-14
5 year+177.39%AUD 0.902021-08-13
Since inception+2,457.68%AUD 0.102007-08-23

Vita Life Sciences Financials at a Glance

Market Cap

A$132.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$172.78M

Net Income (TTM)

A$19.22M

EPS (TTM)

A$0.18

P/E Ratio

13.37

Dividend

A$0.14

Beta (Volatility)

-0.05 (Low)

Price

A$2.45

Volume

4,828

Open

A$2.48

Previous Close

A$2.49

Daily Range

A$2.45 - A$2.49

52-Week Range

A$2.15 - A$2.84

Estimated Earnings Date

Feb 22, 2026

VLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vita Life Sciences

Vita Life Sciences Limited is an Australian healthcare company focused on the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company operates across multiple countries, including Australia, Singapore, and China, offering a diverse range of products targeting various health needs.

Products and Services
  • Vitamins and nutritional supplements for general health
  • Targeted solutions for specific health areas, including immunity and digestion
  • Products marketed under well-known brands like Herbs of Gold and VitaHealth
Growth Outlook
  • Revenue increased to AUD 47.73 million in Q4 2025, up from AUD 39.47 million in Q4 2023
  • Net income rose to AUD 5.60 million in Q4 2025, reflecting strong operational performance
  • Expansion into new markets is expected to drive future revenue growth
Financial Highlights
  • Trailing twelve-month revenue of AUD 182.73 million, indicating consistent demand
  • Net profit margin of 11.19% for the most recent quarter, showcasing profitability
  • Dividend yield of 5.45%, providing attractive returns to shareholders
Vita Life Sciences Limited has established itself as a key player in the healthcare sector, particularly in the vitamins and supplements market. The company's diverse product offerings cater to a wide range of health needs, making it a versatile choice for consumers. Recent financial performance indicates a positive trajectory, with significant revenue growth and a solid net profit margin. The company's commitment to expanding its market presence further enhances its growth potential. With a strong dividend yield, Vita Life Sciences Limited presents an appealing opportunity for investors interested in the healthcare sector.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

CEO

Andrew OKeefe

Headquarters

Mascot, NSW 2020, AU

VLS Financials

Key Financial Metrics (TTM)

Gross Margin

61.15%

Operating Margin

15.71%

Net Income Margin

11.19%

Return on Equity

19.15%

Return on Capital

24.99%

Return on Assets

12.67%

Earnings Yield

7.48%

Dividend Yield

5.62%

Payout Ratio

58.26%

Stock Overview

Market Cap

A$132.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

53.31M

Volume

4.83K

Avg. Volume

9.20K

Financials (TTM)

Gross Profit

A$104.28M

Operating Income

A$26.54M

EBITDA

A$27.08M

Operating Cash Flow

A$22.58M

Capital Expenditure

-A$768.00K

Free Cash Flow

A$21.81M

Cash & ST Invst.

A$35.56M

Total Debt

A$2.39M

Vita Life Sciences Performance Analysis

Vita Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 66,886,00017.1%
20232023-12-31AUD 73,427,0009.8%
20242024-12-31AUD 79,505,0008.3%
20252025-12-31AUD 93,270,00017.3%
Vita Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-0.0%
Q42024-12-311.5%
Q22025-06-3013.7%
Q42025-12-314.8%
Vita Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD 0.13-16.0%
20232023-12-31AUD 0.1726.5%
20242024-12-31AUD 0.16-4.9%
20252025-12-31AUD 0.1816.1%
Vita Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-13.6%
Q42024-12-314.5%
Q22025-06-305.4%
Q42025-12-3113.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$47.73M

+20.9%

Gross Profit

A$29.65M

+29.3%

Gross Margin

62.12%

N/A

Market Cap

A$132.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$331.83K

N/A

Employees

400

N/A

Net Income

A$5.60M

+9.8%

EBITDA

A$7.88M

+7.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$35.56M

+44.4%

Total Debt

A$2.39M

+518.3%

Accounts Receivable

A$13.64M

+21.6%

Inventory

A$15.08M

+35.2%

Long Term Debt

A$1.91M

+985.8%

Short Term Debt

A$482.00K

+14.2%

Return on Assets

12.67%

N/A

Return on Invested Capital

25.19%

N/A

Free Cash Flow

A$9.99M

+27.4%

Operating Cash Flow

A$9.83M

+16.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONE.AXOneview Healthcare PLC
A$0.17+3.13%
ALC.AXAlcidion Group Limited
A$0.09-2.20%
RCE.AXRecce Pharmaceuticals Ltd
A$0.38+1.33%
SDI.AXSDI Limited
A$1.40+0.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About VLS

What is the current price of Vita Life Sciences?

Vita Life Sciences is trading at A$2.45 per share.

What is the 52-week range for Vita Life Sciences?

Over the past 52 weeks, Vita Life Sciences has traded between A$2.15 and A$2.84.

How much debt does Vita Life Sciences have?

As of the most recent reporting period, Vita Life Sciences reported total debt of A$2.39M.

How much cash does Vita Life Sciences have on hand?

Vita Life Sciences reported A$35.56M in cash and cash equivalents in its most recent financial results.

What is Vita Life Sciences’s dividend yield?

Vita Life Sciences currently has a dividend yield of 5.62%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.